Nephron recalls albuterol inhalation solution

Nephron Pharmaceuticals has announced a voluntary recall of ten lots of albuterol inhalation solution “as a precautionary measure, due to results from . . . internal monitoring processes.” The company says that it has not received reports of reportable adverse events for the 0.083% solution and that the lots met Nephron’s quality specifications when manufactured.

The lots involved in the recall are A3A33A, A3A33B, A3A34A, A3A35A, A3A36A, A3A37A, A3A38A, A3A40A, A3A41A, and A3A42A. Nephron has requested that retailers pull the lots from their shelves and is advising consumers to dispose of any inhalation solution from those lots.

The company added that it is “ready to work with every affected customer to ensure that the recall is not disruptive for the supply of this important drug product.”

Read the Nephron Pharmaceuticals press release.

Share

published on

July 13-July 162026 ISAM Congress, Taipei, Taiwan

September 15-September 18DDL New Researcher Network Summer Event, London, UK

September 16-September 17IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA

September 24-September 25Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK